Switching from tirzepatide to retatrutide: what is known

Reviewed 16 sourcesPublished by PepVault

No trial has tested a switch from tirzepatide to retatrutide. What each drug's trials and the Zepbound label say, how the two differ, and what is still unknown.

A man in an olive henley carrying a wooden crate of vegetables through a farmers’ market
Last reviewed
Sources
16
Questions
8
Compounds
2

The short answer

No trial has tested a switch from tirzepatide to retatrutide. Retatrutide's phase 3 weight and diabetes trials excluded anyone who had taken a weight-loss drug in the 90 days before screening, and TRIUMPH-5, the head-to-head trial, assigns each person to one drug. Tirzepatide's half-life is about 5 days, retatrutide's about 6. Retatrutide is not approved, so a change belongs with a prescriber or a trial.

Every number checked at its primary source · · 16 sources · How we research

Evidence: No study of switching exists; this draws on randomised phase 1b, phase 2 and phase 3 trials of each drug, the Zepbound prescribing information and ClinicalTrials.gov records, with some figures from Lilly's releases (company statements). Retatrutide is investigational and not approved.

A man in an olive henley carrying a wooden crate of vegetables through a farmers’ market

Has any trial tested switching from tirzepatide to retatrutide?

No. No retatrutide record on ClinicalTrials.gov studies a switch, and the weight and diabetes trials enroll people who were not on a weight-loss drug when they joined. TRIUMPH-1, the large phase 3 obesity trial, lists among its exclusions anyone who has "taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening", and anyone whose weight changed by more than 5 kg in those 90 days2. TRIUMPH-2, in people with type 2 diabetes, carries the same two lines3. The phase 2 obesity trial excluded people using medications that promote weight loss4, and TRANSCEND-T2D-1, a diabetes trial, excludes any medication meant to promote weight reduction in the 90 days before screening5.

TRIUMPH-5 is the one trial that puts the two drugs side by side. It is a phase 3, double-blind study in about 800 adults with obesity, with or without type 2 diabetes14, that randomly assigns each person to retatrutide or to tirzepatide and compares weight change at 80 weeks1. It has the same 90-day exclusion, so it tests which drug works better from a fresh start, not what happens when someone moves from one to the other1. The registry lists it as active and not recruiting, with its primary completion estimated for November 20261, and Lilly calls it ongoing14. No results have been posted1.

A timeline: the 90 days before screening with no weight-loss drug and weight steady within 5 kg, then screening and randomisation to one drug
Retatrutide's phase 3 weight and diabetes trials started here, so their numbers describe people coming to the drug fresh.

So the retatrutide results in this guide come from people who were not on a weight-loss drug when they joined, and in phase 3 had been off one for at least 90 days. How a body already used to tirzepatide responds to retatrutide's first weeks is unmeasured.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault's dose log keeps every shot with its date, and finishing a protocol keeps its record, so the last tirzepatide dose stays on file.

Download on the App Store

7 days free on the yearly plan for new subscribers.

How are tirzepatide and retatrutide different?

Both are once-weekly injections made by Lilly. Tirzepatide is a dual agonist: it switches on two gut-hormone receptors, GIP and GLP-1, which turn appetite down and slow the stomach6. Retatrutide is a triple agonist: one peptide that works the GIP and GLP-1 receptors and also the glucagon receptor7. In lab tests its activity is balanced between the glucagon and GLP-1 receptors, with more at GIP, and in obese mice the glucagon arm added extra energy burned on top of eating less7. That added burn has been shown in mice; the human trials measured weight.

WhatTirzepatide (Zepbound)Retatrutide
ReceptorsGIP and GLP-16GIP, GLP-1 and glucagon7
Half-lifeAbout 5 to 6 days6About 6 days, phase 1b in type 2 diabetes8
Start2.5 mg weekly for 4 weeks, label62 mg weekly in phase 3, as studied13
Step pace2.5 mg at a time, at least 4 weeks apart6Every 4 weeks, through 4, 6 and 9 mg, as studied in TRIUMPH-113
Top dose15 mg, label maximum612 mg, highest phase 3 arm10
Weight change, top dose (separate trials)−20.9% at 72 weeks, SURMOUNT-111−25.0% at 80 weeks, TRIUMPH-110
Dysesthesia (skin tingling), top dose (separate trials)0.4% vs 0.1% placebo612.5% vs 0.9% placebo13
StatusFDA-approvedInvestigational, not approved anywhere14
Two keys and their locks: tirzepatide’s key fits the GIP and GLP-1 receptors; retatrutide’s fits those two and the glucagon receptor
Tirzepatide works two receptors; retatrutide adds the glucagon receptor. Look at the third lock: the glucagon receptor is the one retatrutide adds.

The weight and skin rows come from separate trials with different people and lengths, so they are not a head-to-head result. TRIUMPH-5 will give the direct comparison. The retatrutide steps are what the trials studied, not a schedule for anyone.

What does the Zepbound label say about missed doses and other drugs?

The label has no section on switching to another drug, and none on restarting after a long break. What it does say6:

  • A missed dose: take it as soon as possible within 4 days (96 hours). After more than 4 days, skip it and take the next dose on the usual day.
  • Changing the day: allowed, as long as two doses are at least 3 days (72 hours) apart.
  • Other drugs: using Zepbound with other tirzepatide products or with any GLP-1 receptor agonist is not recommended. Retatrutide works the GLP-1 receptor too.
  • Why it climbs: the step-up schedule is there to reduce stomach side effects, and the 2.5 mg start is for starting only, not a maintenance dose.

Retatrutide has no label at all: no approved start, no missed-dose rule and no guidance on coming from another drug14.

How long does tirzepatide stay in the body after the last shot?

A half-life is the time it takes for half of a drug to clear. Tirzepatide's is about 5 days, and on weekly shots it reaches a steady level, where each dose replaces what cleared, after 4 weeks6. After the last shot the level halves about every 5 days: roughly half is left at day 5, a quarter at day 10 and an eighth at day 15. A drug is usually treated as mostly gone after four to five half-lives, about three to four weeks for tirzepatide's 5 to 6 days. That is arithmetic on the label's half-life, not a waiting time any study has set for a switch.

Try it

How Tirzepatide builds up

An estimate from a half-life of about 5 days, one dose a week for four weeks. The shape of the level, not a measurement.

Try your own scheduleTirzepatide in the library

A fade curve of tirzepatide after the last weekly shot, halving about every 5 days: half left at day 5, a quarter at day 10, an eighth at day 15 and about 3% at day 25
After the last tirzepatide shot the level halves about every 5 days. Look at day 25: about 3% is left. Arithmetic on the label's half-life, not a switching schedule.

Stopping has a measured cost, though no trial has measured a short gap. In SURMOUNT-4, people who lost an average of 20.9% over 36 weeks on their highest tolerated tirzepatide dose (10 or 15 mg) and were then moved to placebo gained back 14.0% of their body weight over the next 52 weeks, while those who stayed on tirzepatide lost another 5.5%12.

What did the first weeks of retatrutide look like in the trials?

In TRIUMPH-1, every arm started at 2 mg once weekly and stepped up every four weeks to its target of 4, 9 or 12 mg13. In phase 2, starting at 2 mg rather than 4 mg partly eased the stomach side effects, which were dose-related and mostly mild to moderate9. These were people coming to the drug fresh. Whether someone tolerant of tirzepatide would feel the 2 mg start the same way was not studied, and no trial gives a conversion from a tirzepatide dose to a retatrutide one.

PepVault's guide Retatrutide dosage: the trial step-ups lays out every arm and step, and Retatrutide week by week follows appetite and weight through the same trials.

What side effects would be new on retatrutide?

The stomach effects are the familiar ones from tirzepatide: nausea, diarrhoea, constipation and vomiting were the most common side effects in TRIUMPH-113. Two things stand out. Dysesthesia, an unusual skin feeling such as tingling, burning or extra sensitivity, was far more common on retatrutide than the Zepbound label reports for tirzepatide (see the table); in TRIUMPH-1 it was generally mild to moderate, mostly resolved during treatment, and most people kept going13. In phase 2, the heart rate rose with the dose, peaked at 24 weeks and declined after9.

More people stopped at the top dose. In TRIUMPH-1, 4.1% on 4 mg, 6.9% on 9 mg and 11.3% on 12 mg stopped because of side effects, against 4.9% on placebo13. What helps in the step-up weeks is ordinary: smaller meals, eating slowly and stopping at the first sign of fullness, steady fluids, and more fibre and water for constipation.

Commonly reported: appetite suppression even stronger than on tirzepatide, stomach effects after each step-up that settle within one to two weeks, and a higher resting heart rate.

Severe stomach pain that does not go away, sometimes spreading to the back, or vomiting that stops you keeping fluids down is a reason to get medical care the same day.

Can you get retatrutide legally today?

Only inside Lilly's programme. Lilly states that retatrutide has not been approved by the FDA or any regulator anywhere, and that it cannot be legally sold or marketed for human use14. It is legally available to participants in Lilly's trials13, and since June 2026 the registry also lists a pre-approval expanded access programme16. That programme is for adults with a BMI of 35 or more despite the highest available dose of a weight-management drug, two or more serious obesity-related conditions, and no reachable trial; the treating physician makes the request16. Lilly plans to file for FDA approval in the first quarter of 202715.

What should you have ready before talking to a prescriber?

  1. Write down the date and strength of your last tirzepatide dose.
  2. Write down how your weight has moved over the last three months, including any plateau.
  3. List the side effects you had at each tirzepatide step and how long each lasted.
  4. Ask whether a retatrutide trial or the expanded access programme fits you, and what the plan would be for the weeks in between.

PepVault's dose log keeps every shot with its date, and finishing a protocol keeps its record, so the last tirzepatide dose stays on file. Log it in PepVault

Its weight log and side-effect log show the trend and each symptom with its severity and date. Track your weight in PepVault

Track it in the app

Sources

  1. ClinicalTrials.gov NCT06662383 (TRIUMPH-5). A study of retatrutide (LY3437943) compared to tirzepatide (LY3298176) in adults who have obesity (phase 3; sponsor Eli Lilly and Company). clinicaltrials.gov
  2. ClinicalTrials.gov NCT05929066 (TRIUMPH-1). A study of retatrutide (LY3437943) in participants who have obesity or overweight (phase 3; sponsor Eli Lilly and Company). clinicaltrials.gov
  3. ClinicalTrials.gov NCT05929079 (TRIUMPH-2). A study of retatrutide (LY3437943) in participants with type 2 diabetes mellitus who have obesity or overweight (phase 3; sponsor Eli Lilly and Company). clinicaltrials.gov
  4. ClinicalTrials.gov NCT04881760. A study of LY3437943 in participants who have obesity or are overweight (phase 2; sponsor Eli Lilly and Company). clinicaltrials.gov
  5. ClinicalTrials.gov NCT06354660 (TRANSCEND-T2D-1). Retatrutide compared with placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone (phase 3; sponsor Eli Lilly and Company). clinicaltrials.gov
  6. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information. DailyMed, version 40, August 2026. dailymed.nlm.nih.gov
  7. Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022. PubMed 35985340
  8. Urva S et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022. PubMed 36354040
  9. Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023. PubMed 37366315
  10. Jastreboff AM et al.; TRIUMPH-1 Investigators. Retatrutide, a triple hormone receptor agonist, for treatment of obesity. N Engl J Med. 2026. PubMed 42814954
  11. Jastreboff AM et al.; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022. PubMed 35658024
  12. Aronne LJ et al.; SURMOUNT-4 Investigators. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024. PubMed 38078870
  13. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. Press release, May 21, 2026. prnewswire.com
  14. Eli Lilly and Company. Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial (TRANSCEND-T2D-2). Press release, Oct 28, 2026. prnewswire.com
  15. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes. Press release, Sept 29, 2026. prnewswire.com
  16. ClinicalTrials.gov NCT07629401. Pre-approval expanded access of retatrutide (LY3437943) (sponsor Eli Lilly and Company). clinicaltrials.gov

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo